No one can blame you but there aren't a lot of options for PPMS. With that in mind, if you consider the risk of side effects acceptible, you might view entrance into the clinical trial as a situation in which you only stand to gain.....and if you end up on the placebo you are no worse off.Smilingface wrote:My problem with considering the trial is that I don't want the placebo!
FTY720 is a once-daily oral medication with a novel mode of action offering the potential of an innovative approach to MS treatment. It is the first sphingosine-1-phosphate (S1P) receptor modulator.
FTY720 differs from currently approved treatments because it is the only medication that binds the receptors of S1P, present on the surface of lymphocytes, which are a subpopulation of white blood cells. In MS, lymphocytes circulating in the central nervous system (e.g. the brain and spinal cord) attack the myelin sheath that surrounds and protects nerve fibers (axons) which are responsible for transmitting nerve signals to other parts of the body.
As a consequence of receptor binding, the lymphocytes can no longer respond to the molecule that signals them to circulate to sites of inflammation in the body and they stay in the lymph nodes. However, the lymphocytes remain functional and may still be activated within the lymph nodes as part of the immune response.
I think it was bromley who spoke of hearing from a neuro that FTY-720 assists mylination? which could have something to do with the improvement (apart from its main mode of action)dreddk wrote:...been in the FTY 720 trial, and has seen some pretty dramatic improvements (EDSS 5.5 to 2.0 on the trial)
Users browsing this forum: No registered users